Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Alendronate Versus Placebo in the Treatment of HIV-associated Osteoporosis (ANRS120)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Non-pregnant~* Non menopausal women~* Total femur BMD below -2.5 SD (T score) or lumbar spine BMD below -2.5 SD (T score) or BMD below -1 associated with a vertebral osteoporotic fracture (diminution of vertebral height over 20%)~* HIV infection known for at least 5 years~* CD4 cell count over 50/mm3~* Karnofsky score over or equal to 70~* Written informed consent.~Exclusion Criteria:~* Osteoporosis resulting from a cause other than HIV: vitamin D deficiency (in that case, after receiving high-dose calcium and vitamin D for 1 month, patients will be randomized without a new screening), renal failure, heart failure (NHYA class III or IV), treatment with glucocorticoid at a dose over or equal to 0.5mg/kg/d for 15 days or more at time of inclusion or during the previous 6 months; thyroid or other endocrine disease if untreated for more than 6 months; hypercalciuria~* Testosterone below normal if treatment is hormonal~* BMI below or equal to 18~* Severe lung failure~* Chronic alcohol intoxication~* Ongoing opportunistic infection~* Gastric ulcer of disease interfering with oesophageal motility in the previous 3 months~* History of treatment for osteoporosis~* History of malignancy in the previous 5 years (except skin cancer and Kaposi)~* Cytotoxic chemotherapy or cytokine therapy~* Liver cirrhosis~* Breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).